

Product Update

timolol, 1mg/g eye gel for single-dose container (Tiopex®) (No. 941/14) **Spectrum Thea Pharmaceuticals Limited**

10 January 2014

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

timolol gel eye drops (Tiopex®) are accepted for restricted use within NHS Scotland.

Indication under review: reduction of the elevated intraocular pressure in patients with:

- ocular hypertension,
- chronic open angle glaucoma.

SMC restriction: to use in patients who have proven sensitivity to preservatives.

The cost of this once daily preservative-free formulation is significantly cheaper than the twice daily preservative-free preparation and may for some patients offer advantages in the lower concentration and reduced applications.

Preserved timolol eye drops are included in the drug tariff and are significantly cheaper than preservative-free preparations.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 18 November 2013.

**Chairman,
Scottish Medicines Consortium**